- $91.13m
- $81.41m
Annual balance sheet for eXoZymes, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS/A | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Cash and Short Term Investments | 0.548 | 0.559 | 0.067 | 9.72 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | 0.468 | 0.81 | 0.882 | 0.737 |
| Prepaid Expenses | ||||
| Total Current Assets | 1.05 | 1.47 | 1.21 | 10.8 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 1.3 | 1.22 | 2.34 | 2.21 |
| Total Assets | 2.35 | 2.69 | 3.56 | 13 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 0.401 | 0.634 | 2.42 | 1.33 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 1.15 | 1.31 | 3.94 | 2.61 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Total Equity | 1.2 | 1.37 | -0.384 | 10.4 |
| Total Liabilities & Shareholders' Equity | 2.35 | 2.69 | 3.56 | 13 |
| Total Common Shares Outstanding |